2024预见ASCO | 胃食管癌和肝胆胰肿瘤重磅研究一览|单抗|治疗|胰腺癌|放化疗|癌症患者

分享至

一年一度的肿瘤界“奥斯卡”——2024年美国临床肿瘤学会（ASCO）年会将于当地时间5月31日-6月4日在美国芝加哥盛大召开，众多国际重磅的临床科研成果将在ASCO大会期间披露。本文将聚焦胃食管癌和肝胆胰肿瘤，一起看看那些有望改变临床实践的重磅研究！

全体大会

Plenary Session

摘要号：LBA1

标题：Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).

前瞻性随机多中心III期ESOPEC试验，比较食管腺癌患者的围手术期化疗（FLOT方案）和新辅助放化疗（CROSS方案）。

报告人：Jens Hoeppner

单位：University of Bielefeld

在研疗法-免疫治疗

Developmental Therapeutics—Immunotherapy

摘要号：2501

标题：Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.

Claudin18.2靶向嵌合抗原受体T细胞治疗胃肠道癌症患者：CT041-CG4006 I期试验的最终结果。

报告人：齐长松

单位：北京大学肿瘤医院

摘要号：2504

标题：Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.

抗CCR8单克隆抗体LM-108联合抗PD-1抗体治疗胃癌患者的有效性和安全性：I/II期研究结果。

报告人：Chang Liu

单位：北京大学肿瘤医院

摘要号：2519

标题：Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.

抗CLDN18.2/CD3双特异性抗体IBI389应用于实体瘤、胃或胃食管肿瘤的安全性和初步疗效结果：一项I期剂量递增和扩展研究。

报告人：Li Zheng

单位：四川大学华西医院

胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Oral Abstract Session

摘要号：4000

标题：A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).

局部区域性食管和胃食管交界处腺癌患者应用围手术期纳武利尤单抗联合伊匹木单抗治疗，II/III期ECOG-ACRIN EA2174研究的新辅助病理完全缓解（pCR）率结果。

报告人：Jennifer Rachel Eads

单位：University of Pennsylvania, Abramson Cancer Center

摘要号：LBA4001

标题：Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.

单纯化疗/单纯靶向治疗对比化疗/靶向治疗序贯根治性手术对局限转移性胃或胃食管交界处腺癌患者生存时间和生活质量的影响：III期IKF-575/RENAISSANCE试验。

报告人：Salah-Eddin Al-Batran

单位：Krankenhaus Nordwest, University Cancer Center Frankfurt and Frankfurter Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest

摘要号：LBA4002

标题：Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.

雷莫西尤单抗联合紫杉醇作为换药维持治疗，对比奥沙利铂为基础的化疗持续维持治疗应用于晚期HER2阴性胃或胃食管交界处癌：III期ARMANI试验。

报告人：Filippo Pietrantonio

单位：Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori

摘要号：4003

标题：A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.

吉西他滨+白蛋白紫杉醇对比5-FU+KV+伊立替康脂质体治疗初治型老年转移性胰腺癌患者（GIANT）：随机II期ECOG-ACRIN EA2186研究。

报告人：Efrat Dotan

单位：Fox Chase Cancer Center

摘要号：LBA4004

标题：Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.

胰腺癌标志性分层治疗-01：PASS-01试验的早期结果。

报告人：Jennifer J. Knox

单位：Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto

摘要号：4005

标题：NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).

NRG Oncology/RTOG 0848研究：壶腹周围胰腺癌患者接受辅助化疗+/-放化疗治疗的结果。

报告人：Karyn A. Goodman

摘要号：4006

标题：Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial.

全身化疗中联合立体定向放射治疗（SBRT）应用于局部晚期胆管癌：随机II期ABC-07试验的结果。

报告人：Maria A Hawkins

单位：University College London

摘要号：4007

标题：International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).

瑞戈非尼联合帕博利珠单抗治疗既往接受免疫检查点抑制剂治疗的晚期肝细胞癌的国际性、开放标签、II期研究。

报告人：Anthony B. El-Khoueiry

单位：Norris Comprehensive Cancer Center, University of Southern California

摘要号：LBA4008

标题：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

纳武利尤单抗+伊匹木单抗对比仑伐替尼或索拉非尼作为不可切除肝细胞癌（uHCC）的一线治疗：CheckMate 9DW的首次结果披露。

报告人：Peter Robert Galle

单位：University Medical Center Mainz

Rapid Oral Abstract Session

摘要号：4012

标题：Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.

卡度尼利单抗联合pulocimab和紫杉醇作为免疫化疗失败的晚期胃或胃食管交界处(G/GEJ)癌症患者二线治疗的疗效和安全性：一项多中心、双盲、随机试验。

报告人：张小田

单位：北京大学肿瘤医院

摘要号：4013

标题：Use of artificial intelligence–based digital pathology to predict outcomes for immune checkpoint inhibitor therapy in advanced gastro-esophageal cancer.

使用基于人工智能的数字病理学来预测免疫检查点抑制剂治疗晚期胃食管癌的结果。

报告人：Feyisope Eweje

单位：Department of Radiation Oncology, Stanford University School of Medicine

摘要号：LBA4014

标题：Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.

吉西他滨联合白蛋白紫杉醇对比同步放化疗联合S-1作为临界可切除胰腺癌的新辅助治疗：随机II/III期GABARANCE研究。

报告人：Masafumi Ikeda

单位：Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East

摘要号：4015

标题：Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.

人工智能辅助转录组特征的开发和验证，用于指导可切除胰腺导管腺癌患者的个性化辅助化疗。

报告人：Nelson J. Dusetti

单位：Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University

摘要号：4016

标题：Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma..

早发性胰腺癌与正常发病胰腺癌的肿瘤微生物组差异。

报告人：Thejus Jayakrishnan

单位：Taussig Cancer Center

摘要号：4017

标题：A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

阿替利珠单抗+varlilumab（CDX-1127）联合或不联合cobimetinib用于经治型不可切除胆道癌的随机II期研究。

报告人：Thatcher Ross Heumann

单位：DVanderbilt-Ingram Cancer Center

摘要号：4018

标题：Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment.

sitravatinib联合替雷利珠单抗治疗至少1次全身治疗失败的晚期胆道癌的II期研究。

报告人：Jeesun Yoon

单位：Department of Internal Medicine, Seoul National University Hospital; Cancer Research Institute, Seoul National University

摘要号：4019

标题：Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).

C-CAR031，一种GPC3特异性TGFβRIIDN的自体armored-CAR-T，应用于晚期肝细胞癌（HCC）的I期研究。

报告人：章琦

单位：浙江大学医学院附属第一医院

摘要号：4020

标题：Safety, tolerability and efficacy of ²¹²Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.

²¹²Pb-DOTAMTATE作为靶向α治疗应用于不可切除或转移性生长抑素受体表达胃肠胰神经内分泌肿瘤（SSTR+GEP-NETs）的安全性、耐受性和有效性：一项II期研究。

报告人：Jonathan R. Strosberg

单位：H. Lee Moffitt Cancer Center and Research Institute

Clinical Science Symposium

摘要号：107

标题：The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial.

对于早期胰腺癌，直接手术后行连续循环肿瘤DNA（ctDNA）检测在辅助化疗决策中的潜在指导作用：AGITG DYNAMIC-Pancreas试验。

报告人：Belinda Lee

单位：Northern Health, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, University of Melbourne

摘要号：4009

标题：Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).

维迪西妥单抗联合替雷利珠单抗和S-1作为HER2过表达的晚期胃或胃食管交界处腺癌患者一线治疗的疗效：一项多中心、单臂、II期试验。

报告人：刘联

单位：山东大学齐鲁医院

摘要号：4010

标题：A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.

一种新型独特设计的针对晚期恶性肿瘤和神经内分泌癌的靶向PD-L1和4-1BB的双特异性抗体：LBL-024单药治疗的开放标签、多中心、剂量递增/扩展、首次人体试验的安全性和疗效研究报告。

报告人：张攀攀

单位：北京大学肿瘤医院

摘要号：4011

标题：Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.

抗CLDN18.2/CD3双特异性抗体IBI389治疗晚期胰腺导管腺癌患者的安全性和有效性：I期研究的初步结果

报告人：郝继辉

单位：天津医科大学肿瘤医院

备注：排名不分先后，按照摘要号进行

如有遗漏或任何问题，请给我们留言~

撰写：Babel

排版：Babel

执行：Babel

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。

Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.